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Key Points
• In the largest study of
HMAs in RR-AML to
date, 16% of patients
achieved CR/CRi and
experienced a median
OS of 21 months.
• Low proliferative dis-
ease (peripheral blood
blasts ,5%) was as-
sociated with improved
response and OS.
Although hypomethylating agents (HMAs) are frequently used in the frontline treatment of
older acute myeloid leukemia (AML) patients, little is known about their effectiveness in
relapsed or primary treatment–refractory (RR)-AML. Using an international multicenter
retrospective database, we studied the effectiveness of HMAs in RR-AML and evaluated for
predictors of response and overall survival (OS). A total of 655 patients from 12 centers
received azacitidine (57%) or decitabine (43%), including 290 refractory (44%) and 365
relapsed (56%) patients. Median age at diagnosis was 65 years. Best response to HMAs
was complete remission (CR; 11%) or CR with incomplete count recovery (CRi; 5.3%).
Additionally, 8.5% experienced hematologic improvement. Median OS was 6.7 months (95%
confidence interval, 6.1-7.3). As expected, OS differed significantly by best response, with
patients achieving CR and CRi having a median OS of 25.3 and 14.6 months, respectively. In
multivariate analysis, the presence of #5% circulating blasts and a 10-day schedule of
decitabine were associated with improved response rates, whereas the presence of .5%
circulating blasts and .20% bone marrow blasts were associated with decreased OS. A
significant subset of RR-AML patients (16%) achieved CR/CRi with HMAs and experienced a
median OS of 21months. Outside of a clinical trial, HMAs represent a reasonable therapeutic
option for some patients with RR-AML.
Introduction
Although intensive chemotherapy (IC) remains the standard of care for younger and more functionally
fit individuals with acute myeloid leukemia (AML), patients with advanced age or poor performance
status are often not treated with IC because of concerns for increased treatment-related morbidity
and mortality, as well as inherent biologic disease resistance to cytotoxic therapy.1-3 For these patients,
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low-dose cytarabine and the hypomethylating agents (HMAs) azaciti-
dine and decitabine have been increasingly used as less-intensive
treatment options.1,4,5
The prognosis of older patients with relapsed or primary
treatment–refractory AML (RR-AML) is particularly poor, with a
median overall survival (OS) of only 3 to 7 months.6 There is no
standard salvage therapy for RR-AML.1,2,7 The role of HMAs in
patients with RR-AML after failure of IC is not well studied, with data
limited to small and/or single-institution retrospective studies.8-10
The objective of this international retrospective study was to
examine the patterns of use and efficacy of HMAs in a multicenter
cohort of RR-AML patients and to assess for clinical and laboratory
markers that could identify patients most likely to benefit from
HMAs.
Patients and methods
Data source and eligibility
Deidentified data were collected by the individual centers, and the
datasets were combined and analyzed at the coordinating center
(Yale University). All patients aged $16 years with a pathologically
confirmed World Health Organization (WHO)–defined AML (with
$20% marrow blasts at time of diagnosis) who had received
azacitidine or decitabine after relapse of AML or after failure of
induction with$1 course of IC were included in the study. Patients
were not selected based on response to therapy, and patients who
relapsed after allogeneic stem cell transplantation (alloSCT) were
included in this study. Data were collected spanning the period from
2006 to 2016. The participating centers included 12 large
academic centers: 7 in the United States and 5 in Europe. There
was no central review of the pathology, and the responses were
determined by the local investigators. The study was approved by
the institutional review boards of the authors’ institutions and was
conducted in accordance with the Declaration of Helsinki.
Relapse of AML was defined as the recurrence of .5% blasts in
the peripheral blood (PB) and/or bone marrow (BM) of patients
after achieving a complete remission (CR), whereas primary
treatment-refractory AML was defined as the lack of achievement
of CR or CR with incomplete count recovery (CRi) after therapy
with$1 course of IC.11 Duration of the first CR was defined as the
duration between CR achievement and the date of relapse and
was set to 0 in patients with refractory AML.
Patient characteristics
When available, clinical and laboratory data were collected at the
time of diagnosis, as well as at initiation of HMA. Cytogenetics were
classified according to the Modified British Medical Research
Council classification.12,13 Molecular data, including mutations in
the FLT3, NPM1,CEBPa, TP53, DNMT3A, TET2, IDH1/2, ASXL1,
and SF3B1 genes, were collected when available. Additional data
extracted include the specific type of HMA (azacitidine or decitabine),
the administration regimen, the number of cycles, and any concurrent
therapy used along with HMAs.
Response criteria and survival
The primary end point of the study was OS, whereas the
secondary end points included rates of CR and CRi. Best
response was evaluated according to the 2003 revised In-
ternational Working Group (IWG) AML criteria11 and was
assigned by the investigator providing the data. Other response
end points, including achievement of hematologic improvement
(HI), stable disease (SD), and progressive disease (PD), as
defined by the 2006 modified IWG criteria for myelodysplastic
syndromes (MDS), were also collected.14 Response duration
was measured from the date of response to progression or
death, whichever happened sooner. OS was measured from
time of initiation of HMAs until death or last follow-up.
Statistical analysis
Descriptive statistics were calculated to characterize the study cohort.
We used the Student t test and x2 test to compare continuous and
categorical variables, respectively. Missing data were imputed using the
multivariate imputation by chained equation approach, implemented with
the mice package in R, with 10 iterations per variable.15 Details of the
imputation methods are provided in the supplemental data. Survival
outcomes were assessed at the last follow-up. Median OS was
estimated with the Kaplan-Meier method, and the log-rank test was used
to assess survival differences between groups. Univariate andmultivariate
Cox proportional hazards and logistic regression models assessed the
association of covariates with OS and response rates, respectively
(supplement data). All tests were 2-sided, with an a significance level of
0.05. All analyses were performed using R version 3.3.2.
Results
Study population
A total of 655 patients was studied, of whom 365 (56%) had
relapsed and 290 (44%) had refractory AML (Table 1). By the end
of the study, 87% of the patients had died. Median age at diagnosis
was 65 years (range, 16-92). In total, 70% of patients had been
diagnosed with de novo AML. Of the 30%who had secondary AML,
27% had therapy-related AML. The median number of prior
therapies was 1 (range, 1-7); 26% had received 2 prior lines of
therapy, and 18% had received $3 prior lines. Prior alloSCT was
performed in 19% of patients. Among all patients, only 2% harbored
a good-risk karyotype, whereas 40% had a poor-risk karyotype.
Chromosome 5 and 7 abnormalities and a monosomal karyotype
were reported in 20%, 22%, and 16% of patients, respectively.
Data regarding FLT3, NPM1, and TP53 mutational status at the
time of diagnosis were available in 269, 228, and 93 patients,
respectively, of whom 17%, 24%, and 8% were reported to have
FLT3, NPM1, or TP53 mutations, respectively. Information about
other mutations was only available in a minority of patients, with
IDH1/2 and CEBPa being the most commonly reported.
At the onset of HMA treatment, median white blood cell count
(WBC) was 3.2 3 109/L (range, 0.1-110.5 3 109/L), with only 20
patients having WBCs .50 3 109/L; 254 (55.9%) patients had
platelet counts ,50 3 109/L, and 220 (53.0%) had absolute
neutrophil counts ,1.0 3 109/L. Median BM blast percentage
was 24%, with 213 patients (55.0%) having .20% BM blasts
at the time of HMA initiation. A total of 272 patients (69.4%) had
blasts detected in the blood, whereas 120 patients (30.6%) had
no blasts detected in the blood (for 263 patients data regarding PB
blasts was missing).
Patterns of treatment with HMA
Azacitidine was used in 57% of patients, whereas decitabine was
administered in the other 43%. The median number of azacitidine
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Table 1. Patient characteristics
All patients (N 5 655) Relapsed patients (n 5 365) Refractory patients (n 5 290)
PMedian or n Range or % Median or n Range or % Median or n Range or %
Age, y (n 5 636) 65 16-92 65 16-89 64 19-92 .8197
Sex (N 5 655) .5432
Male 381 58.2 208 57 173 59.7
Female 274 41.8 157 43 117 40.3
AML type (n 5 650) .0065
De novo 458 70.5 272 74.9 186 64.8
Secondary 192 29.5 91 25.1 101 35.2
WHO type at diagnosis (n 5 651)
AML with recurrent genetic abnormalities 38 5.8 31 8.5 7 2.4 .0020
AML with myelodysplasia-related features 175 26.9 86 23.6 89 31.1 .0385
Therapy-related AML 52 8 31 8.5 21 7.3 .6952
AML, not otherwise specified 386 59.3 217 59.5 169 59.1 .9899
CBC prior to initiation of HMA
WBC (n 5 455) 3.2 0.1-110.5 3.2 0.1-110.5 3.3 0.1-79.8 .2843
ANC (n 5 415) 0.9 0-72 1 0-72 0.8 0-54 .7160
Platelets (n 5 454) 40 0.6-810 44 2-293 35 0.6-810 .4455
PB blast % (n 5 392) 8 0-98 8 0-96 8 0-98 .4862
BM prior to initiation of HMA
BM blast % (n 5 305) 27 2-100 27 2-100 26.5 2-95 .5606
BM cellularity % (n 5 244) 40 2-100 40 2-100 40 2-100 .2496
MRC cytogenetic risk group prior to initiation of
HMA (n 5 225)
.7794
Good 4 1.8 3 2.5 1 1
Intermediate 131 58.2 70 57.9 61 58.7
Poor 90 40 48 39.7 42 40.4
Chromosomal abnormalities
Complex (n 5 224) 54 24.1 29 24 25 24.3 1
Monosomy (n 5 234) 37 15.8 20 15.6 17 16 1
Chromosome 7 abn (n 5 224) 50 22.3 28 23.1 22 21.4 .8744
Chromosome 5 abn (n 5 224) 44 19.6 21 17.4 23 22.3 .4441
Mutational status (prior to start of HMA or at
diagnosis)
TP53 (n 5 93) 7 7.5 5 7.7 2 7.1 1
FLT3 (n 5 269) 46 17.1 34 20.9 12 11.3 .0622
NPM1 (n 5 228) 55 24.1 42 30.7 13 14.3 .0076
CEBPa (n 5 124) 8 6.5 7 8.3 1 2.5 .4349
DNMT3A (n 5 39) 5 12.8 3 11.1 2 16.7 .6342
TET2 (n 5 37) 2 5.4 2 7.4 0 0 1
IDH1/2 (n 5 39) 5 12.8 4 13.8 1 10 1
ASXL1 (n 5 11) 0 0 0 0 0 0 1
SF3B1 (n 5 7) 0 0 0 0 0 0 1
Number of therapy lines prior to HMA (n 5 648) 1 1-7 1 1-7 1 1-7 .8463
Duration of CR1 prior to initiation of HMA (n 5 329) 1.95 0-180 8 0.5-180 0 0-0 ,.0001
AlloSCT prior to initiation of HMA (months) (n5 618) 115 18.6 91 27 24 8.5 ,.0001
HMA used (n 5 634) .1695
Azacitidine 360 56.8 192 54.2 168 60
Decitabine 274 43.2 162 45.8 112 40
abn, abnormality; ANC, absolute neutrophil count; MRC, Modified British Medical Research Council.
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cycles was 3 (range, 1-36), compared with 2 for decitabine (range,
1-35; P 5 .5) (Table 1). Among patients who were treated with
azacitidine, 76.5% received the US Food and Drug Administration–
approved 7-day (7-0) schedule of azacitidine, whereas 17.9% and
2.4% of patients used a 5-day (5-0) and a 7-day schedule with a
weekend break (5-2-2), respectively. Among decitabine users, the
drug was given on a 5-day (5-0), 7-day (7-0), and 10-day (10-0)
schedule in 72.1%, 1.2%, and 19.9% of patients, respectively
(Table 1). HMAs were stopped in the majority of patients because of
progression of disease (55.5%) or because no response was
achieved with HMAs (27.6%), whereas in a smaller group of
patients, they were stopped because of the treatment protocol
(9.1%) or side effects (6.3%); 1.4% of patients were still receiving
HMAs at the time of the study.
A total of 146 patients (28%) received other therapeutic agents in
combination with azacitidine and decitabine; the most frequently
used were gemtuzumab ozogamicin and valproic acid (Table 1).
Following HMA therapy, 62% of patients did not receive any
further therapy; 37 patients (5.6%) underwent alloSCT (Table 2).
Response to HMA therapy and predictors
Best responses achieved with HMA therapy were CR in 11%, CRi
in 5.3%, HI in 8.5%, and SD in 7.4%, whereas 67.9% of patients
had PD (Table 2). Among patients who achieved CR/CRi, the
response duration was limited, with a median of 8.5 months (95%
CI, 8.3-15.1). The median duration of CR was 10 months (95%
confidence interval [CI], 8-17.3), whereas it was 8.4 months
(95% CI, 5.2-14.5; P 5 .4) for CRi. The CR/CRi rate was not
significantly different between relapsed and refractory AML patients
(P 5 .09). Similarly, response duration did not differ between
refractory and relapsed AML patients (P5 .3). Results of univariate
logistic regression analysis are provided in supplemental Table 1.
Table 1. (continued)
All patients (N 5 655) Relapsed patients (n 5 365) Refractory patients (n 5 290)
PMedian or n Range or % Median or n Range or % Median or n Range or %
Number of cycles of HMA (n 5 633) 3 1-36 3 1-36 3 1-34 .4922
Azacitidine 3 1-36 3 1-36 4 1-34 .4684
Decitabine 2 1-35 2 1-35 2 1-22 .8129
HMA administration schedule (n 5 587) .3654
Azacitidine (n 5 336)
7-0 257 76.5 131 73.2 126 80.3
5-2-2 18 2.4 10 5.6 8 5.1
5-0 60 17.9 38 21.2 22 14.0
10-0 1 0.3 0 0 1 0.6
Decitabine (n 5 251)
7-0 3 1.2 1 0.7 2 1.8
5-2-2 2 0.8 0 0 2 1.8
5-0 181 72.1 104 73.8 77 70.0
10-0 50 19.9 29 20.6 21 19.1
Others 15 6.0 7 5.0 8 7.3
Agents used concurrently with HMA (n 5 532) .0585
Gemtuzumab ozogamicin 64 12 25 9 39 15.4
Valproic acid 7 1.3 2 0.7 5 2
Valproic acid plus all-trans retinoic acid 24 4.5 11 3.9 13 5.1
Hydroxyurea 12 2.3 5 1.8 7 2.8
Cytarabine 2 0.4 1 0.4 1 0.4
Anthracycline 4 0.8 0 0 4 1.6
Sorafenib 13 2.4 10 3.6 3 1.2
Hedgehog inhibitor 4 0.8 1 0.4 3 1.2
IDH inhibitor 1 0.2 0 0 1 0.4
Erythrocyte-stimulating agents 7 1.3 5 1.8 2 0.8
Granulocyte colony-stimulating factor 8 1.5 4 1.4 4 1.6
JAK 1 0.2 1 0.4 0 0
Dead at end of study (n 5 608) 529 87 295 86.8 234 87.3 .9376
abn, abnormality; ANC, absolute neutrophil count; MRC, Modified British Medical Research Council.
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In a multivariate logistic-regression analysis, variables that were
significantly associated with higher odds of achieving CR/CRi
included presence of #5% PB blasts (odds ratio [OR], 1.87; 95%
CI, 1.07-3.26; P 5 .0278) and a 10-day schedule of decitabine
(OR, 2.37; 95% CI, 1.05-5.33; P 5 .0374). Age, sex, Eastern
Cooperative Oncology Group (ECOG) performance status of the
patient, disease status (refractory vs relapsed AML), WHO subtype
of AML, cytogenetic risk group, and the use of a specific type of
HMA did not significantly affect the odds of achieving CR/CRi
(Figure 3A; supplemental Table 2).
OS after HMA treatment and predictors
The 30-day mortality from the date of HMA initiation was 6.4% (95%
CI, 4.6-8.8). Median OS from the time of initiation of HMA was 6.7
months (95% CI, 6.1-7.3) for the entire study population (Figure 1A;
Table 2). The OS correlated significantly with the best response
achieved with HMA therapy (Figure 1B; Table 2). MedianOSwas 25.3
months (95% CI, 17-30.2) or 14.6 months (95% CI, 9.5-32) for
patients achieving a CR or CRi, respectively. The OS of those who
achieved CR or CRi as their best response to HMA therapy was
significantly better than the OS of patients who demonstrated PD
(median OS, 4.5 months; 95% CI, 4.1-5.3 for patients with PD;
P, .0001 for both comparisons). Patients who achieved HI or SD as
their best response to HMA therapy had a median OS of 11.7 months
(95% CI, 9.4-14.6 months) or 10.4 months (95% CI, 8.7-14 months),
respectively; these results were significantly higher than the OS of
patients who developed PD (P , .0002 for both comparisons,
Figure 1B; Table 2). In a landmark analysis, at 2, 4, and 6 months from
the start of HMA treatment, the effect of response to HMA (CR1CRi)
on OS remained significant. In landmark analyses, the median OS for
responders vs nonresponders was 21.9 vs 5.1 months, 19.9 vs 5.1
months, and 19.3 vs 4.9 months at 2, 4, and 6 months, respectively (all
log-rank P, .0001). Survival curves did not change significantly when
follow-upwas assessed at the time of alloSCT (supplemental Figure 1).
In the univariate and multivariate Cox proportional hazards model for
OS, the presence of circulating blasts (PB blasts . 5% vs #5%,
hazard ratio [HR], 1.29; 95% CI, 1.05-1.58; P 5 .02) and .20%
blasts in the BM (BM blasts . 20% vs #20%, HR, 1.24; 95% CI,









(n 5 63) P
Response (n 5 638), n (%) Relapsed vs refractory 5 .0248, alloSCT vs no
alloSCT , .0001
CR 70 (11) 41 (11.6) 29 (10.2) 18 (28.6)
CRi 34 (5.3) 25 (7.1) 9 (3.2) 15 (23.8)
HI 54 (8.5) 21 (5.9) 33 (11.6) 2 (3.2)
SD 47 (7.4) 24 (6.8) 23 (8.1) 8 (12.7)
PD 433 (67.9) 242 (68.6) 191 (67.0) 20 (31.7)
OS based on response (n 5 621),
median (95% CI), mo
6.7 (6.1-7.3) 6.2 (5.6-7.4) 7 (6.4-8.9) 12.5 (9.7-17) Relapsed vs refractory 5 .47, alloSCT vs no
alloSCT , 0.0001
CR 25.3 (17-30.2) 23.9 (16.8-46.2) 25.3 (16.7-Inf) 17.7 (15.3-Inf)
CRi 14.6 (9.5-32) 11.7 (9.5-Inf) 16.1 (8.9-Inf) 11.7 (9.5-Inf)
HI 11.7 (9.4-14.6) 9.4 (7.8-46.5) 11.7 (9.7-14.9) 9.4 (NA)
SD 10.4 (8.7-14) 8.7 (5.8-16.4) 10.6 (9.1-17.7) 16.4 (10.6-Inf)
PD 4.5 (4.1-5.3) 4.7 (3.9-5.6) 4.4 (3.8-5.9) 6.7 (4.5-16.6)
OS based on HMA used (n 5 621),
median (95% CI), mo
Azacitidine 6.8 (6-8.5) 6.3 (5.3-8.4) 7.5 (6.5-9.4) 16.1 (9.5-Inf) Relapsed vs refractory = 0.532, alloSCT vs no
alloSCT = 0.0237
Decitabine 6.2 (5.3-7.3) 6.2 (5.3-8.4) 6.5 (4.4-7.7) 11.7 (9.3-17.7) Relapsed vs refractory = 0.969, alloSCT vs no
alloSCT , 0.0001
Duration of response (n 5 62), median (range), mo 8.5 (1-84) 10 (1-84) 5 (2-36.9) 5 (1-36.9) Relapsed vs refractory 5 .3112, alloSCT vs no
alloSCT 5 .4014
Reason for discontinuation of HMA
(n 5 492), n (%)
Relapsed vs refractory 5 .0905, alloSCT vs no
alloSCT , .0001
Intolerance 31 (6.3) 18 (6.4) 13 (6.2) 2 (3.2)
No response 136 (27.6) 65 (23) 71 (33.8) 8 (12.7)
Progression of disease 273 (55.5) 170 (60.3) 103 (49) 24 (38.1)
End of protocol 45 (9.1) 25 (8.9) 20 (9.5) 29 (46)
Ongoing treatment, n (%) 7 (1.4) 4 (1.4) 3 (1.4) 0 (0)
Number of lines of therapy after HMA failure
(n 5 612), median (range)
0 (0-6) 0 (0-5) 0 (0-6) 1 (0-6) Relapsed vs refractory 5 .6315, alloSCT vs no
alloSCT 5 .0004
AlloSCT after HMA therapy (n 5 629), n (%) 37 (5.6) 16 (43.2) 21 (56.8) — Relapsed vs refractory 5 .5108
Inf, infinity; NA, not applicable.
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1.01-1.53; P 5 .04) were significant predictors for inferior OS.
Additionally, in univariate analysis, a longer duration of CR1
(duration of CR1. 12 months vs#12 months, HR, 0.74; 95% CI
0.58-0.93; P 5 .01) was associated with better OS, whereas a
lower platelet count (platelet count # 30 3 109/L vs .30 3 109/L,
HR, 1.31; 95% CI 1.07-1.6; P 5 .008), more lines of prior therapy
(2 vs 1 prior line of therapy, HR, 1.25; 95% CI 1.02-1.5; P 5 .03),
and the use of decitabine (decitabine vs azacitidine, HR, 1.2;
95% CI 1.02-1.45; P 5 .03) were associated with shorter OS
(Figures 1C, 2A, and 3B; supplemental Tables 3 and 4). The age,
sex, ECOG performance status of the patient and the disease
status (refractory vs relapsed AML), WHO subtype of AML, and
cytogenetic risk group did not significantly affect survival with
HMA therapy (Figures 2B and 3B; supplemental Tables 3 and 4).
In contrast to the effects on achieving CR/CRi, the schedule of
HMA therapy did not have a significant impact on OS. Patients
who used the 10-day schedule of decitabine did not have a
better OS than patients receiving any other schedule of HMA
(HR, 0.87; 95% CI, 0.62-1.24; P5 .46) (supplemental Figure 1C;
supplemental Table 4). The mutational status (TP53, FLT3, and
NPM1 mutations) did not have an impact on OS (supplemental
Figure 1D-E; supplemental Tables 3 and 4). The combination of
additional agents with HMA therapy did not improve OS or
response rates.
Discussion
To our knowledge, this international study represents the largest
reported experience of HMA use in patients with RR-AML.8-10,16-18
As expected, patients in this cohort were older (median age 65
years) and exhibited high-risk disease features, such as poor-risk
karyotypes (40%) and secondary AML (30%). Although the OS for
the entire cohort was poor (median, 6.7 months), a significant
subset of patients (16%) achieved CR/CRi with HMAs and
achieved a median OS of 21.2 months (95% CI, 16.3-28.6).
For this cohort of RR-AML with many patients exhibiting high-risk
features, the observed CR/CRi rates appear reasonable and compare
favorably with rates that can be achieved with other lower-intensity
therapy options (eg, low-dose cytarabine, clofarabine) in the relapsed
and refractory (RR) setting.6,19-21 Although the CR/CRi rate with
HMAs in the RR setting in our study was lower compared with the use
of azacitidine in elderly AML patients, with .30% BM blasts in the
frontline setting (CR/CRi 27.8%),5 the median OS for patients who
achieved a CR/CRi was impressive for patients in the RR setting
(Figure 1B). Although most patients progressed eventually on HMA
therapy, the response duration of 8.5 months for CR/CRi (CR 10
months, 95% CI, 8-17.3; CRi 8.4 months, 95% CI, 5.2-14.5) was
comparable to the duration of CR/CRi (10.5 months) in older AML

































































Figure 1. Outcome for all patients based on response achieved and type of treatment used. (A) OS probability from onset of HMA treatment in the global cohort.
OS probability from onset of HMA treatment according to AML IWG response criteria (for CR/CRi/PD) and MDS IWG response criteria (SD/HI) (B) and according to HMA
used (azacitidine vs decitabine) (C).
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Similar to what was observed in the setting of IC for AML, achievement
of CR was associated with a trend for improved OS compared with
CRi (25.3 vs 14.6 months; P 5 .05). Although HI and SD are not
formally identified objective responses in AML, compared with MDS,
the achievement of HI and SD in our cohort was associated with
improved OS compared with those who had PD (Figure 1B). These
observations support the efforts of refining existing criteria or
establishing new criteria associated with meaningful clinical benefit in
AML, such as those recently seen in clinical trials of novel agents, such
as IDH inhibitors, FLT3 inhibitors, and venetoclax.22-24
Given the low response rates associated with HMAs in AML, there
have been efforts to identify predictors of clinical benefit. However, no
consistently predictive clinical, pathological, or laboratory parameters
have been identified. In one study of older RR-AML patients, higher
PB blast counts were associated with worse response rates to HMA
therapy, whereas high-risk cytogenetics and PB blasts .10% were
predictive of inferior OS in a multivariate analysis.8 Similarly, in our
much larger cohort, worse response rates and OS were predicted by
a higher percentage of blasts in the PB and the BM (for OS), which
argues for HMAs being more effective in AML patients with lower
proliferation rates. We did not observe an adverse prognostic impact
for poor-risk cytogenetics after IC failure, which was reported in prior
studies (Figure 2B).6,8,25-28 Neither age nor WBC at relapse, which
are prognostic markers for salvage IC, had a significant prognostic
impact on OS in our cohort of patients treated with HMAs.6,25 The
prognostic impact of molecular information in RR-AML is under-
studied and controversial.25,29 In a multivariate analysis of patients
with RR-AML, shorter CR1 duration was associated with decreased
OS, but FLT3 and NPM1 mutation status was not significantly
associated with OS.29 Similarly, in our study, NPM1 and FLT3
mutational status was not significantly associated with response
or OS.
In a recent study of AML and MDS patients treated with 10-day
cycles of decitabine, response rates were higher in patients with
unfavorable-risk cytogenetic abnormalities compared with those
with intermediate- or favorable-risk cytogenetics.30,31 All patients
with TP53 mutations responded to decitabine, and the OS for
patients with TP53 mutations was not significantly different from the
OS seen in patients without the mutations and was longer than that
historically observed in such patients treated with more aggressive
therapies.32,33 Our patients with poor-risk cytogenetics and TP53
mutations similarly did not have a statistically significant worse OS
compared with patients with intermediate/good-risk cytogenetics and
no TP53 mutations, respectively (Figure 3B).
Azacitidine and decitabine have not been directly compared in the
setting of RR-AML in randomized prospective trials. In our analysis,
the response rates and OS associated with azacitidine and
decitabine were not significantly different in multivariate analyses,
whereas decitabine-treated patients had worse OS compared with
azacitidine-treated patients in univariate analyses. Interestingly,
patients receiving the 10-day schedule of decitabine had a higher
CR/CRi rate than patients who received other HMA schedules
(28% vs 15.7%, P5 .04). The higher response rate associated with
a 10-day schedule of decitabine in our study is intriguing, because
longer exposure to decitabine might lead to improved efficacy,10,34
and in the above-mentioned study, a 10-day schedule of decitabine
led to surprisingly high response and OS rates in a high-risk patient
population.30,31 However, given the retrospective nature of our
study with potential differences in characteristics between groups
of patients receiving different HMAs on various schedules, it is
impossible to conclude with certainty whether the prolonged
administration of decitabine had a causal effect on response rates.
Furthermore, the improved response rate seen with a 10-day
schedule of decitabine in multivariate analyses did not translate to a
difference in OS (8 months vs 6.6 months, P 5 .13) in multivariate
analyses, although an association between CR/CRi and improved
survival was observed in the entire cohort.
Like any other retrospective study, selection bias is an important
limitation. Furthermore, all patients were treated in specialized
tertiary care centers, and this may impact the broad applicability of
the data. We did not specifically measure or qualify comorbidities
that might influence patient outcomes. We also did not measure
days of hospitalization or side effects associated with HMAs,
although the investigators reported that only a minority of patients
(6%) stopped HMAs because of intolerance, and the 30-day
mortality was relatively low (6.4%) compared with IC.
It is important to recognize that to achieve a CR with HMA
treatment, a sufficient number of cycles of HMAs is required .The
median number of azacitidine cycles was 3 (range, 1-36) compared
with 2 for decitabine (range, 1-35; P5 .5). We did not have detailed
information available regarding why treatment was stopped early in
some patients. Additionally, patient frailty is often not identified by
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Figure 2. Outcome based on PB blast percentage, as well as cytogenetic
markers. OS probability from onset of HMA treatment according to PB blast percentage
(.5% vs #5%) (A) and cytogenetic risk (intermediate/normal vs poor) (B).
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surrogate markers for frailty in this study. In this context, it would
have been helpful if there had been universal adoption of geriatric
measures or formal comorbidity screening. Finally, molecular
mutation data were missing for many patients.
The value of our study is that it helps to inform the discussion
between providers and patients regarding HMAs as a treatment
option for RR-AML, shows the urgent need for improved
therapeutic options, and serves as a valuable reference in the
development of future clinical trial using HMAs as the backbone.
Our study shows that 16% of RR-AML patients achieved CR/CRi with
HMA therapy, which is associated with a survival benefit. Although this
remission rate is objectively low, it is comparable to other salvage
approaches in RR-AML, and therapies with HMAs provide a manage-
able side effect profile that allows for outpatient therapy. For these
reasons, HMAs are a reasonable therapeutic option for patients with
RR-AML in the absence of clinical trial options.
Future efforts should focus on identifying predictive factors to
select patients who are most likely to derive benefit from HMA
therapy and on rationally designing combination-based trials using
agents that exhibit synergistic effects with HMAs. Because many
future HMA-based combination studies will be conducted as
single-arm studies before proceeding to a randomized study, our
efficacy data for HMAs in RR-AML in this very large and diverse
cohort serve as an important reference point for the design of
these trials.
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Figure 3. Forrest plots from multivariate analysis. Forrest plot for prognostic factors of response (CR1CRi) (A) and mortality (B).
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